查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586058

癌症疫苗市場：按技術、治療方法和應用分類 - 2025-2030 年全球預測

Cancer Vaccines Market by Technology (Antigen, Dendritic Cells, Recombinant Cancer Vaccines), Treatment Method (Preventive Vaccine, Therapeutic Vaccine), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年癌症疫苗市值為179億美元，預計2024年將達205.6億美元，複合年成長率為15.37%，到2030年將達到487.1億美元。

癌症疫苗代表了腫瘤學在預防和治療應用方面的關鍵進步。這些疫苗刺激人體的免疫系統辨識和消滅癌細胞，防止高危險群發生癌細胞或治療現有的惡性。癌症疫苗具有廣泛的靶點，針對子宮頸癌、肝癌和胃癌等多種癌症，並受到免疫治療意識增強和技術創新的推動。這種需求源於癌症發病率的不斷上升，這推動了對更有針對性和更有效的治療方法的需求。主要用途包括預防性疫苗（例如人類乳突病毒(HPV)疫苗）和抑制癌症（例如黑色素瘤）復發和轉移的治療型疫苗。最終用途包括醫院、癌症研究機構和癌症診所，主要市場在美國、歐洲和亞太地區。

主要市場統計
基準年[2023] 179億美元
預測年份 [2024] 205.6億美元
預測年份 [2030] 487.1億美元
複合年成長率（%） 15.37%

確定了關鍵的成長要素，包括抗原發現的進步、生物技術研發投資的增加以及透過公私合營增加資金籌措。對個人化醫療的日益關注以及吸引精準治療愛好者的基於新抗原的疫苗的開發已經成熟。創業家應該利用這些趨勢，探索突破性疫苗試驗的夥伴關係，並利用人工智慧來改善抗原辨識。然而，嚴格的監管條件、高昂的開發成本和有限的熟練人力資源等挑戰構成了主要障礙。此外，漫長的臨床試驗過程和不同癌症類型的療效差異也限制了市場的成長。

最具創新性的領域涉及探索將癌症疫苗與查核點抑制劑和其他免疫調節劑結合的聯合治療。專注於開發具有成本效益的疫苗生產流程可以緩解財務限制。透過利用基因組定序的進步，我們可以進一步個人化疫苗反應並改善患者的治療結果。簡而言之，癌症疫苗市場是動態的，只要能夠有效克服障礙，就有可能透過創新和策略聯盟顯著成長。

市場動態：揭示快速發展的癌症疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變癌症疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加導致癌症患者增加
    • 提高患者對癌症治療的認知
    • 人類乳突病毒 (HPV) 感染發生率增加
  • 市場限制因素
    • 開發成本高
  • 市場機會
    • 增加對癌症疫苗開發的投資和政府資助
    • 癌症疫苗技術開發
  • 市場挑戰
    • 生產一種疫苗所需的時間長度

波特五力：駕馭癌症疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癌症疫苗市場的影響

外部宏觀環境因素在塑造癌症疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症疫苗市場的競爭狀況

癌症疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣癌症疫苗市場供應商績效評估

FPNV定位矩陣是評估癌症疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪癌症疫苗市場的成功之路

癌症疫苗市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於人口老化的增加，癌症患者數量增加
      • 提高患者對癌症治療的認知
      • 人類乳突病毒 (HPV) 感染發生率增加
    • 抑制因素
      • 癌症疫苗研發成本高
    • 機會
      • 增加對癌症疫苗開發的投資和政府資助
      • 癌症疫苗的技術開發
    • 任務
      • 生產一種疫苗需要很長時間
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症疫苗市場：依技術分類

  • 抗原
  • 樹突狀細胞
  • 重組癌症疫苗
  • 病毒載體和 DNA 癌症疫苗
  • 全細胞癌症疫苗

第7章依治療方式分類的癌症疫苗市場

  • 預防性疫苗
  • 治療性疫苗

第8章癌症疫苗市場：依應用分類

  • 子宮頸癌
  • 攝護腺癌

第9章美洲癌症疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區癌症疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲癌症疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Advaxis Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • Dynavax Technologies
  • GSK PLC
  • Helsinn Healthcare SA
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Sanpower Group Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA0514B

The Cancer Vaccines Market was valued at USD 17.90 billion in 2023, expected to reach USD 20.56 billion in 2024, and is projected to grow at a CAGR of 15.37%, to USD 48.71 billion by 2030.

Cancer vaccines represent a pivotal advancement in oncology, aimed at both prophylactic and therapeutic applications. These vaccines function by stimulating the body's immune system to identify and destroy cancer cells, either preventing onset in high-risk individuals or treating existing malignancies. The scope of cancer vaccines is broad, addressing various cancers such as cervical, liver, and gastric cancers, driven by heightened awareness and technological innovation in immunotherapy. Necessity arises from the growing cancer prevalence, driving demand for more targeted, effective treatment modalities. Key applications include preventive vaccines like the HPV vaccine and therapeutic types aiding in reducing recurrence and metastasis in cancers such as melanoma. The end-use scope spans hospitals, cancer research institutes, and specialized oncology clinics, with the U.S., Europe, and Asia-Pacific regions being critical markets.

KEY MARKET STATISTICS
Base Year [2023] USD 17.90 billion
Estimated Year [2024] USD 20.56 billion
Forecast Year [2030] USD 48.71 billion
CAGR (%) 15.37%

Insights reveal significant growth factors, including advancements in antigen discovery, rising investment in biotech R&D, and collaborations between public-private sectors enhancing funding. Opportunities are ripe in the growing focus on personalized medicine and the development of neoantigen-based vaccines, appealing to precision therapy enthusiasts. Entrepreneurs should explore partnerships for breakthrough vaccine trials and leverage AI for improved antigen identification to capitalize on these trends. However, challenges such as stringent regulatory landscapes, high development costs, and limited skilled personnel pose significant hurdles. Additionally, market growth is constrained by slow clinical trial processes and varying efficacy across cancer types.

The best innovation areas include exploring combination therapies integrating cancer vaccines with checkpoint inhibitors and other immunomodulatory agents. Emphasis on developing cost-effective vaccine manufacturing processes can mitigate financial restraints. Leveraging advancements in genome sequencing can further personalize vaccine responses, leading to better patient outcomes. In essence, the cancer vaccines market is dynamic, with vast potential for growth driven by innovation and strategic alliances, provided the barriers are effectively navigated.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Vaccines Market

The Cancer Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in number of cancer patients along with growing geriatric population
    • Surge in patient awareness towards cancer therapy
    • Increase in prevalence of human papilloma virus (HPV) infections
  • Market Restraints
    • High cost for developing cancer vaccines
  • Market Opportunities
    • Increase in investments and government funding in development of cancer vaccines
    • Technological developments in cancer vaccines
  • Market Challenges
    • Longer time span required for manufacturing a single vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Vaccines Market

A detailed market share analysis in the Cancer Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Vaccines Market

A strategic analysis of the Cancer Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Vaccines Market, highlighting leading vendors and their innovative profiles. These include Advaxis Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Celldex Therapeutics, Dynavax Technologies, GSK PLC, Helsinn Healthcare SA, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Sanpower Group Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Antigen, Dendritic Cells, Recombinant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, and Whole-cell Cancer Vaccines.
  • Based on Treatment Method, market is studied across Preventive Vaccine and Therapeutic Vaccine.
  • Based on Application, market is studied across Cervical Cancer and Prostate Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in number of cancer patients along with growing geriatric population
      • 5.1.1.2. Surge in patient awareness towards cancer therapy
      • 5.1.1.3. Increase in prevalence of human papilloma virus (HPV) infections
    • 5.1.2. Restraints
      • 5.1.2.1. High cost for developing cancer vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in investments and government funding in development of cancer vaccines
      • 5.1.3.2. Technological developments in cancer vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Longer time span required for manufacturing a single vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Vaccines Market, by Technology

  • 6.1. Introduction
  • 6.2. Antigen
  • 6.3. Dendritic Cells
  • 6.4. Recombinant Cancer Vaccines
  • 6.5. Viral Vector & DNA Cancer Vaccines
  • 6.6. Whole-cell Cancer Vaccines

7. Cancer Vaccines Market, by Treatment Method

  • 7.1. Introduction
  • 7.2. Preventive Vaccine
  • 7.3. Therapeutic Vaccine

8. Cancer Vaccines Market, by Application

  • 8.1. Introduction
  • 8.2. Cervical Cancer
  • 8.3. Prostate Cancer

9. Americas Cancer Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advaxis Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Celldex Therapeutics
  • 6. Dynavax Technologies
  • 7. GSK PLC
  • 8. Helsinn Healthcare SA
  • 9. Johnson & Johnson
  • 10. Merck & Co., Inc.
  • 11. Novartis International AG
  • 12. Pfizer Inc.
  • 13. Sanofi SA
  • 14. Sanpower Group Co., Ltd.
  • 15. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY ANTIGEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY RECOMBINANT CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR & DNA CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY WHOLE-CELL CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023